Selectis Health (GBCS) Cost of Revenue (2015 - 2025)

Selectis Health (GBCS) has 11 years of Cost of Revenue data on file, last reported at $7.0 million in Q4 2025.

• Quarterly Cost of Revenue fell 10.99% year-over-year to $7.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $31.8 million (up 4.61% YoY) and the FY2025 annual result came in at $31.8 million, up 4.61% from the prior year.
• Cost of Revenue slipped to $7.0 million in Q4 2025 per GBCS's latest filing, from $8.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $8.9 million in Q4 2021, with the low at $3.5 million in Q1 2021.
• Average Cost of Revenue over 5 years is $7.2 million, with a median of $7.5 million recorded in 2024.
• Year-over-year, Cost of Revenue jumped 96.4% in 2022 and retreated 11.85% in 2024.
• Selectis Health's Cost of Revenue stood at $8.9 million in 2021, then retreated by 2.18% to $8.7 million in 2022, then dropped by 10.66% to $7.7 million in 2023, then climbed by 1.61% to $7.9 million in 2024, then retreated by 10.99% to $7.0 million in 2025.
• Business Quant data shows GBCS's Cost of Revenue at $7.0 million in Q4 2025, $8.5 million in Q3 2025, and $8.2 million in Q2 2025.